INBX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Inhibrx received FDA acceptance of its BLA for Ozekibart in conventional chondrosarcomaJun 16, 2026
- Inhibrx reports interim Phase 2 data for INBRX-106 showing potential benefit over PD-1 monotherapy in HNSCCMay 11, 2026
- Inhibrx provided a clinical update on Ozekibart in late-line colorectal cancerApr 22, 2026
- Inhibrx announced a webcast to provide a clinical update on Ozekibart in late-line colorectal cancerApr 21, 2026
- Inhibrx Biosciences reports positive topline results from its registrational trial of Ozekibart (INBRX-109) in chondrosarcoma and provides updates on colorectal cancer and Ewing sarcoma expansion cohortsOct 24, 2025